Read More Pharma Industry News Novo Nordisk seeks FDA nod for Mim8 — how will this impact hemophilia treatment and NVO stock? Novo Nordisk files FDA application for Mim8 in hemophilia A. Learn how flexible dosing and trial data could redefine the bleeding disorder market. byShanvithaSeptember 29, 2025